Taribavirin offers a safe, effective alternative for chronic hepatitis C

Researchers at Cedars-Sinai Medical Centre and 50 other centres found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD)...

Read the whole article on

More from